ConductScience.org, home
Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian Cancers
API referenceFor AI assistants

Trial · NCT05483933

Results by group124

Each measurement the trial posted, group by group, in the words and numbers it posted.

1 to 20 of 124

Download this page as JSON
OutcomeGroupCategoryValueSpreadUnits
Evaluate Safety and Tolerability of SL-172154 When Administered With PLD or MirvetixumabPegylated Liposomal Doxorubicin + SL-17215420Participants
Evaluate Safety and Tolerability of SL-172154 When Administered With PLD or MirvetixumabMirvetixumab + SL-17215465Participants
To Assess Preliminary Evidence of Anti-tumor Activity of SL-172154 When Administered With PLD or MirvetixumabPegylated Liposomal Doxorubicin + SL-172154Complete response0Participants
To Assess Preliminary Evidence of Anti-tumor Activity of SL-172154 When Administered With PLD or MirvetixumabMirvetixumab High (PS2+ ≥75%) + SL-172154Complete response1Participants
To Assess Preliminary Evidence of Anti-tumor Activity of SL-172154 When Administered With PLD or MirvetixumabMirvetixumab Low+Medium ((PS2+ ≥25% to <75%) + SL-172154Complete response0Participants
To Assess Preliminary Evidence of Anti-tumor Activity of SL-172154 When Administered With PLD or MirvetixumabPegylated Liposomal Doxorubicin + SL-172154Partial response4Participants
To Assess Preliminary Evidence of Anti-tumor Activity of SL-172154 When Administered With PLD or MirvetixumabMirvetixumab High (PS2+ ≥75%) + SL-172154Partial response12Participants
To Assess Preliminary Evidence of Anti-tumor Activity of SL-172154 When Administered With PLD or MirvetixumabMirvetixumab Low+Medium ((PS2+ ≥25% to <75%) + SL-172154Partial response4Participants
To Assess Preliminary Evidence of Anti-tumor Activity of SL-172154 When Administered With PLD or MirvetixumabPegylated Liposomal Doxorubicin + SL-172154Stable Disease10Participants
To Assess Preliminary Evidence of Anti-tumor Activity of SL-172154 When Administered With PLD or MirvetixumabMirvetixumab High (PS2+ ≥75%) + SL-172154Stable Disease21Participants
To Assess Preliminary Evidence of Anti-tumor Activity of SL-172154 When Administered With PLD or MirvetixumabMirvetixumab Low+Medium ((PS2+ ≥25% to <75%) + SL-172154Stable Disease13Participants
To Assess Preliminary Evidence of Anti-tumor Activity of SL-172154 When Administered With PLD or MirvetixumabPegylated Liposomal Doxorubicin + SL-172154Progressive Disease6Participants
To Assess Preliminary Evidence of Anti-tumor Activity of SL-172154 When Administered With PLD or MirvetixumabMirvetixumab High (PS2+ ≥75%) + SL-172154Progressive Disease5Participants
To Assess Preliminary Evidence of Anti-tumor Activity of SL-172154 When Administered With PLD or MirvetixumabMirvetixumab Low+Medium ((PS2+ ≥25% to <75%) + SL-172154Progressive Disease9Participants
To Assess Preliminary Evidence of Anti-tumor Activity of SL-172154 When Administered With PLD or MirvetixumabPegylated Liposomal Doxorubicin + SL-172154Not Evaluable0Participants
To Assess Preliminary Evidence of Anti-tumor Activity of SL-172154 When Administered With PLD or MirvetixumabMirvetixumab High (PS2+ ≥75%) + SL-172154Not Evaluable0Participants
To Assess Preliminary Evidence of Anti-tumor Activity of SL-172154 When Administered With PLD or MirvetixumabMirvetixumab Low+Medium ((PS2+ ≥25% to <75%) + SL-172154Not Evaluable0Participants
Immunogenicity to SL-172154Pegylated Liposomal Doxorubicin + SL-1721540Participants
Immunogenicity to SL-172154Mirvetuximab + SL-17215438Participants
Immunogenicity to MIRVMirvetuximab + SL-1721548Participants

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Next page

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT05483933/results

API referenceFor AI assistants